Investigators compared oncologic outcomes among patients with tumors in the bladder only vs in the bladder neck/urethra.

Results from the Phase IIb SunRISe-1 study demonstrated a one-year duration of response with the TAR-200 intravesical ...

Antibody-drug conjugates combined with immunotherapy have redefined the standard of care for advanced bladder cancer, ...

UroGen Pharma's potential remains strong despite market volatility, with promising FDA prospects for UGN-102 & a $5B ...

To grow, cancer tumors must hijack the immune system for their needs. One of the main tricks that most tumors use is to ...

Approximately 10 percent of patients with hematuria will be found to have a bladder tumor. Frequently, however, urine that appears perfectly normal to the naked eye will be shown by the microscope to ...

ImmunityBio, Inc. (NASDAQ: IBRX), a leading immunotherapy company, will announce new clinical findings for ANKTIVA® ...

Normally, TGF-Beta soothes the immune system, and some cancers use it to evade attack. It also triggers a signaling cascade ...

A supplemental Biologics License Application has been submitted to the FDA for Anktiva plus BCG in papillary NMIBC.

This ability to move allows them to be distributed more efficiently in the bladder, reaching tumor cells more precisely and ...

A new, error-corrected method for detecting cancer from blood samples is much more sensitive and accurate than prior methods and may be useful for monitoring disease status in patients following ...